Advertisement
Orexigen management will host the call and webcast to discuss results forthe second quarter ended June 30, 2008, and recent business highlights. Thelive call may be accessed by phone by calling (800) 860-2442 (domestic) or(412) 858-4600 (international). The webcast can be accessed live on theinvestor relations section of the Company's Web site athttp://www.orexigen.com and will be archived for 14 days following the call.
Advertisement
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on thedevelopment of pharmaceutical product candidates for the treatment of centralnervous system disorders, including obesity. The Company's lead combinationproduct candidates targeted for obesity are Contrave(R), which is in Phase IIIclinical trials, and Empatic(TM), which is in the later stages of Phase IIclinical development. Both product candidates take advantage of the Company'sunderstanding of how the brain appears to regulate appetite and energyexpenditure, as well as the mechanisms that come into play to limit weightloss over time. Each product candidate is designed to act on a specific groupof neurons in the central nervous system with the goal of achieving appetitesuppression and sustained weight loss. Further information about the Companycan be found at http://www.orexigen.com.
SOURCE Orexigen Therapeutics, Inc.
